Altimmune (NASDAQ:ALT) Downgraded by Guggenheim to “Neutral”

Guggenheim cut shares of Altimmune (NASDAQ:ALT) from a buy rating to a neutral rating in a research report sent to investors on Monday morning, Marketbeat.com reports.

A number of other research firms also recently commented on ALT. B. Riley reissued a buy rating and set a $20.00 target price on shares of Altimmune in a research report on Thursday, March 28th. The Goldman Sachs Group assumed coverage on shares of Altimmune in a report on Wednesday, January 24th. They set a neutral rating and a $13.00 price objective on the stock. Finally, HC Wainwright lowered their target price on Altimmune from $15.00 to $12.00 and set a buy rating for the company in a report on Monday, April 1st.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $6.40 on Monday. The stock has a 50 day moving average price of $9.24 and a 200 day moving average price of $7.61. The firm has a market capitalization of $453.34 million, a price-to-earnings ratio of -3.88 and a beta of 0.05. Altimmune has a 52-week low of $2.09 and a 52-week high of $14.84.

Altimmune (NASDAQ:ALT) last issued its earnings results on Wednesday, March 27th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.02. The business had revenue of $0.04 million during the quarter. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. Analysts forecast that Altimmune will post -1.52 earnings per share for the current year.

Institutional Trading of Altimmune

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in shares of Altimmune by 63.1% during the 3rd quarter. SG Americas Securities LLC now owns 43,086 shares of the company’s stock valued at $112,000 after purchasing an additional 16,661 shares during the last quarter. Miracle Mile Advisors LLC acquired a new position in Altimmune during the 3rd quarter valued at about $44,000. Barclays PLC raised its stake in Altimmune by 62.0% in the third quarter. Barclays PLC now owns 180,409 shares of the company’s stock valued at $470,000 after buying an additional 69,014 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Altimmune in the third quarter worth about $40,000. Finally, WealthPlan Investment Management LLC acquired a new position in shares of Altimmune during the third quarter valued at about $31,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.